Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

You searched for id:"handle:10211.3/187447". One record found.

Search Limiters

Last 2 Years | English Only

No search limiters apply to these results.

▼ Search Limiters


San Diego State University

1. Liu, Nan. PIM1-Minicircle as a therapeutic treatment for myocardial infarction.

Degree: 2017, San Diego State University

PIM1, a pro-survival gene, encodes a serine/ threonine kinase, is known to influence cell proliferation and survival. Modified cardiac progenitor cells (CPCs) by PIM1 using a lentiviral-based delivery method showed long-term improved cardiac function after myocardial infarction (MI). However, lentiviral based delivery methods have stringent FDA regulation with respect to clinical trials. To provide an alternative and low risk PIM1 delivery method, this study examined the use of a non-viral modified plasmid-minicircle (MC) as a vehicle to deliver PIM1 into mouse CPCs (mCPCs) in vitro and the myocardium in vivo. MC containing a turbo gfp reporter gene (gfp-MC) was used as a transfection and injection control. PIM1 was subcloned into gfp-MC (PIM1-MC) and then transfected into mCPCs at an efficiency of 29.4???3.7%. PIM1-MC engineered mCPCs (PIM1-mCPCs) have a significantly (P<0.05) better survival rate under oxidative treatment. PIM1-mCPCs also exhibited a 1.9???0.1 and 2.2???0.2 fold higher cell proliferation at 3 and 5 days post plating, respectively, as compared to gfp-MC transfected mCPCs control. PIM1-MC was injected directly into ten-week old adult Female FVB mice hearts in the border zone immediately after MI. Delivery of PIM1 into myocardium was confirmed by GFP+ cardiomyocytes. Mice with PIM1-MC injection showed increased protection compared to gfp-MC injection groups measured by ejection fraction at 3 and 7 days post injury (P=0.0379 and P=0.0262 by t-test, respectively). Success of PIM1 delivery and integration into mCPCs in vitro and cardiomyocytes in vivo by MC highlights the possibility of a non-cell based therapeutic approach for treatment of ischemic heart disease and MI in the future. Advisors/Committee Members: Biology, Sussman, Mark A, Bernstein, Sanford, Hong, Mee Young.

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Liu, N. (2017). PIM1-Minicircle as a therapeutic treatment for myocardial infarction. (Thesis). San Diego State University. Retrieved from http://hdl.handle.net/10211.3/187447

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Liu, Nan. “PIM1-Minicircle as a therapeutic treatment for myocardial infarction.” 2017. Thesis, San Diego State University. Accessed August 19, 2017. http://hdl.handle.net/10211.3/187447.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Liu, Nan. “PIM1-Minicircle as a therapeutic treatment for myocardial infarction.” 2017. Web. 19 Aug 2017.

Vancouver:

Liu N. PIM1-Minicircle as a therapeutic treatment for myocardial infarction. [Internet] [Thesis]. San Diego State University; 2017. [cited 2017 Aug 19]. Available from: http://hdl.handle.net/10211.3/187447.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Liu N. PIM1-Minicircle as a therapeutic treatment for myocardial infarction. [Thesis]. San Diego State University; 2017. Available from: http://hdl.handle.net/10211.3/187447

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

.